Electra Therapeutics

Electra Therapeutics Raises $183 Million in Series C - October 22, 2024

Executive Summary

Electra Therapeutics raised an oversubscribed $183 million Series C to advance clinical trials for novel immunology therapies targeting autoimmune and inflammatory diseases.

Funding Amount: $183 Million

Valuation: Undisclosed

Round Type: Series C

Announced: October 22, 2024

Headquarters: Basel, Switzerland

Category: Biotechnology

About Electra Therapeutics

Electra Therapeutics was founded in 2021 and is headquartered in Basel, Switzerland. The company currently employs 80+ people and operates in the Biotechnology sector.

Electra Therapeutics raised an oversubscribed $183 million Series C to advance clinical trials for novel immunology therapies targeting autoimmune and inflammatory diseases.

Funding Round Details

Investment Amount

Electra Therapeutics successfully raised $183 Million in this Series C funding round, announced in October 22, 2024.

The company has not disclosed its valuation.

Lead Investors & Participants

Nextech (Lead Investor): Healthcare-focused venture capital

EQT Life Sciences (Healthcare Investor): European life sciences investor

Sanofi (Strategic Pharma): Global pharmaceutical company

HBM Healthcare Investments (Healthcare Investor): Life sciences specialist

Mubadala Capital (Sovereign Wealth): UAE sovereign investment fund

OrbiMed (Healthcare VC): Leading healthcare investment firm

Redmile Group (Healthcare Hedge Fund): Healthcare-focused investor

RA Capital Management (Healthcare Investor): Biotech investment firm

Use of Funds

Advancing Phase 2 clinical trials for lead immunology drug candidates, expanding pipeline in autoimmune diseases, and preparing for regulatory submissions.

The capital will enable Electra Therapeutics to:

• Accelerate product development and innovation
• Expand market reach and customer acquisition
• Scale operations and infrastructure
• Strengthen the team with key hires
• Invest in research and development

Key Metrics & Achievements

• Multiple Phase 2 trials ongoing
• Targeting multi-billion dollar immunology market
• Novel mechanism of action in autoimmune diseases
• Strategic partnership with Sanofi
• Potential for first approval in 2026-2027

Business Model

Electra develops and commercializes immunology therapies for autoimmune and inflammatory diseases, with potential for partnerships and licensing deals with major pharma companies.

Market Opportunity & Competition

Competes with AbbVie, Johnson & Johnson, and other biotech companies developing immunology therapies for conditions like rheumatoid arthritis and inflammatory bowel disease.

The Biotechnology market continues to experience rapid growth, with increasing demand from enterprises and consumers. Electra Therapeutics is well-positioned to capitalize on this opportunity with its differentiated technology and strong investor backing.

What This Means for the Industry

This significant funding round demonstrates strong investor confidence in Electra Therapeutics's vision and execution. The $183 Million investment positions the company to:

1. Accelerate Innovation: Develop next-generation products and features
2. Expand Market Leadership: Capture greater market share in Biotechnology
3. Scale Operations: Build infrastructure to support rapid growth
4. Attract Top Talent: Recruit world-class engineers, researchers, and business leaders
5. Drive Industry Transformation: Shape the future of Biotechnology

Company Background

Founded: 2021

Headquarters: Basel, Switzerland

Employees: 80+

Industry: Biotechnology

Total Funding: $183 Million+ (this round)

Looking Ahead

With this substantial funding, Electra Therapeutics is positioned for continued growth and innovation in the Biotechnology space. The company plans to leverage the capital to expand its market presence, enhance its product offerings, and solidify its position as a leader in the industry.

Investors and industry analysts will be closely watching Electra Therapeutics as it executes on its ambitious growth plans and works to deliver value to customers and shareholders.

About the Investors

Nextech: Healthcare-focused venture capital

EQT Life Sciences: European life sciences investor

Sanofi: Global pharmaceutical company

This funding announcement was verified through official press releases, SEC filings, and credible news sources including Crunchbase, TechCrunch, and Bloomberg.

Last Updated: October 26, 2025